Table 2.
The characteristics of patient derived PRP application.
| PRP Preparation | |
| Blood volume taken | 72 mL |
| Anticoagulant | Sodium citrate 3.8% (w/v) |
| System | Close |
| Centrifugation | Once, 580 g/8 min |
| Final PRP volume | 10 mL (IO) plus 8 mL (IA) |
| PRP Characteristics | |
| PRP Type | 13-00-11 |
| MPV | 10.1 fL (CI: 9.30–10.50) |
| Red Blood Cells | <0.01 × 106/μL |
| White Blood Cells | <0.05 × 106/μL |
| Activation | CaCl2 10% (w/v) |
| Application Characteristics | |
| Formulation type | Liquid |
| Administration route | IO plus IA |
| Dosage | 2 infiltrations at two weeks interval |
| Volume | IO: 10 mL (5 mL acetabulum + 5 mL femoral head) IA injection: 8 mL |
| Dose (range of platelets) | IO injection: 2.76 × 109–3.98 × 109 IA injection: 2.21 × 109–3.18 × 109 |
| Tissue | Cartilage, synovium, subchondral bone |
| Pathology | Hip osteoarthritis |
PRP: platelet-rich plasma; IA: intraarticular; IO: intraosseous; MPV: mean platelet volume.